COVID-19 Treatments

COVID-19 Treatments

Rolling Collaborative Reviews (RCR)

Please access the RCR project plan and all separate RCR documents, updated on a monthly or bi-monthly basis, in the following table.

*For monthly updated RCRs, the RCR authors search for new available evidence on a monthly basis. If new evidence is available, an updated report is published. In the case that no new evidence can be identified, no update is published, and the search is repeated in the subsequent month.

For bi-monthly updated RCRs, the RCR authors search for new available evidence every other month. If new evidence is available, an updated report is published. In the case that no new evidence can be identified, no update is published and the search is repeated after 2 months.

Please access a description of methods used in the RCR process here.

Stopping & Starting Rules for RCR

Stopping Rules

  • The decision to stop an RCR will be taken collectively in the RCR team.
  • A discussion about stopping an RCR will be started when either stopping rule 1 OR stopping rule 2 is met.
  • The stopping rules act as orientation/ reference for the discussion in the team; an RCR may not be stopped although one of the rules apply if the team comes to a different conclusion due to any sound reason.

Stopping rule 1:

The compound is in EMA’s marketing authorization process or has a positive marketing authorization decision.

Stopping rule 2:

No clinical benefit: ≥ 2 RCTs OR treatment arms in platform trials (e.g., RECOVERY) with negative efficacy and/or safety results in the indication and population under review (phase III, of high or moderate quality/ high or moderate certainty of evidence, well powered).

OR ≥1 RCT with negative efficacy and/or safety results in the indication and population under review (phase III, of high or moderate quality/ high or moderate certainty of evidence, well powered) AND stopped enrollment of participants to the treatment arm of interest in a platform trial (e.g., RECOVERY) because no evidence of beneficial effects.

  • To be considered for the discussion:
    • Amount and number of included patients of ongoing RCTs and upcoming RCTs

Starting rules

  • The decision to start an RCR will be taken collectively in the RCR team.
  • A discussion about starting an RCR will be started when one of the starting rules is met.
  • The starting rules act as orientation/ reference for the discussion in the team; an RCR may not be started although one of the rules apply if the team comes to a different conclusion due to any sound reason.

Starting rule 1:

Published results from ≥ 1 phase III RCT with positive efficacy and safety results in the indication and population under review (high or moderate quality, non peer-reviewed or peer-reviewed article).

  • Confirmed by DEPLazio or RCT found on covid-nma.com

Starting rule 2:

Upcoming (promising) evidence of ≥ 2 phase III trials.

Starting rule 3:

Compound included as trial drug in a platform trial on COVID-19 treatments.

Starting rule 4:

Combination therapy of ≥ 2 promising pharmaceuticals – the combination will be reviewed as a separate intervention.

Starting rule 5:

Interest from ≥ 2 EUnetHTA Partners (via survey) OR Interest from MAH to seek marketing approval OR Interest from EC, HTA Network or EUnetHTA Stakeholder Groups.

 

Rapid Collaborative Reviews

Please access the Rapid Collaborative Reviews in the following table.

Project ID
Title
Version of RCR published
Author
Start of Procedure
Contintuation
Publication of Project Plan
RCR01
Convalescent plasma therapy / CPT
6.0 – 20/01/2021
HTW
August 2020
Yes, monthly
RCR02
Lopinavir + Ritonavir
4.0 – 23/11/2020
National Institute of Pharmacy and Nutrition – NIPN
August 2020
No, stopped with November 2020
RCR03
Tocilizumab
6.0 – 20/01/2021
National Institute of Pharmacy and Nutrition – NIPN
August 2020
Yes, monthly
RCR04
Camostat
5.0 – 16/12/2020
Belgian Health Care Knowledge Centre – KCE
August 2020
Yes, monthly
RCR05
Nafamostat
5.0 – 16/12/2020
Belgian Health Care Knowledge Centre – KCE
August 2020
Yes, monthly
RCR06
Solnatide
4.0 – 16/12/2020
Austrian Institute for Health Technology Assessment – AIHTA
August 2020
Yes, bi-monthly
RCR07
Anakinra
6.0 – 20/01/2021
Austrian Institute for Health Technology Assessment – AIHTA
August 2020
Yes, monthly
RCR08
Dexamethasone
2.0 – 15/09/2020
Austrian Institute for Health Technology Assessment – AIHTA
August 2020
No, stopped with October 2020
RCR09
APN01
4.0 – 16/12/2020
Agencia Española De Medicamentos Y Productos Sanitarios – AEMPS, Andalusian HTA Agency,
Andalusian HTA Agency, Ministry of Health – AETSA
August 2020
Yes, bi-monthly
RCR10
Darunavir
6.0 – 26/01/2021
Swiss Network for HTA – SNHTA
August 2020
Yes, monthly
RCR11
Favipiravir
6.0 – 25/01/2021
Swiss Network for HTA – SNHTA
August 2020
Yes, monthly
RCR12
Sarilumab
6.0 – 20/01/2021
Norwegian Institute of Public Health – NIPH
August 2020
Yes, monthly
RCR13
Interferon and Novaferon
5.0 – 20/01/2021
Norwegian Institute of Public Health – NIPH
September 2020
Yes, monthly
RCR14
Gimsilumab
2.0 – 15/09/2020
State Medicines Control Agency of Lithuania – SMCA
August 2020
Yes, bi-monthly
RCR15
Canakinumab
3.0 – 16/11/2020
State Medicines Control Agency of Lithuania – SMCA
August 2020
Yes, bi-monthly
RCR16
REGN-COV2 (Casirivimab + Imdevimab)
2.0 – 20/01/2021
Austrian Institute for Health Technology Assessment – AIHTA
December 2020
Yes, monthly
RCR17
Bamlanivimab (LY-CoV555)
2.0 – 20/01/2021
Austrian Institute for Health Technology Assessment – AIHTA
December 2020
Yes, monthly
RCR18
Baricitinib (LY3009104)
2.0 – 20/01/2021
Austrian Institute for Health Technology Assessment – AIHTA
December 2020
Yes, monthly
RCR19
Molnupiravir (MK 4482/ EIDD-2801
2.0 – 20/01/2021
Austrian Institute for Health Technology Assessment – AIHTA
December 2020
Yes, monthly
RCR20
High-dose vitamin D
TBD
Gesundheit Österreich GmbH – GÖG
February 2021
Yes, monthly
RCR21
Mavrilimumab
1.0 – 20/01/2021
Servicio de Evaluación del Servicio Canario de la Salud – SESCS
January 2021
Yes, monthly
RCR22
Ivermectin
TBD
Agency for Health Technology Assessment and Tariff System – AOTMiT
February 2021
Yes, monthly
RCR23
Aspirin
TBD
Swiss Network for HTA – SNHTA
February 2021
Yes, monthly

National HTA Organisation Treatment Links

Links will be published here that relate to relevant partner organisation outputs on Covid-19.

Austrian Institute for Health Technology Assessment (AIHTA) – Horizon scanning for Covid-19 treatments:

http://eprints.aihta.at/1234/

 

 

National HTA Organisation Treatment Links

Links will be published here that relate to relevant partner organisation outputs on Covid-19.

Austrian Institute for Health Technology Assessment (AIHTA) – Horizon scanning for Covid-19 treatments:

http://eprints.aihta.at/1234/

CountryOrganisationDate of publicationHTA reviews/assessments on Covid testing
UKNICE
National Institute for Health and Care Excellence

1/20/21COVID-19 rapid evidence summary: Sarilumab for COVID-19
UKNICE
National Institute for Health and Care Excellence

1/15/21COVID-19 rapid evidence summary: Sarilumab for COVID-19
ItalyAIFA
1/13/21Vaccini COVID-19 (Covid-19 vaccines)
PortugalINFARMED
National Authority of Medicines and Health Products

12/23/20Vacinas COVID-19 (Covid-19 vaccines)
SpainAEMPS
12/15/20Sospechas de reacciones adversas notificadas con tratamientos utilizados en COVID-19 (Suspected adverse reactions reported with treatments used in COVID-19)
FranceHAS
12/1/20Aspects immunologiques et virologiques de l’infection par le SARS-CoV-2 (Immunological and virological aspects of SARS-CoV-2 infection)
ItalyAIFA11/25/20Idrossiclorochina nella terapia dei pazienti adulti con COVID-19 (Hydroxychloroquine in the treatment of adult patients with COVID-19)
ItalyAIFA
11/25/20Idrossiclorochina nella terapia dei pazienti adulti con COVID-19 (Hydroxychloroquine in the treatment of adult patients with COVID-19)
ItalyAIFA
11/24/20Eparine a basso peso molecolare nei pazienti adulti con COVID-19 (Low molecular weight heparins in adult patients with COVID-19)
ItalyAIFA
11/24/20Remdesivir nella terapia dei pazienti adulti con COVID-19 (Remdesivir in the therapy of adult patients with COVID-19)
FranceHAS
11/10/20Tests diagnostiques pour différencier la COVID-19 des infections respiratoires hivernales en période de co-circulation des virus (Diagnostic tests to differentiate COVID-19 from winter respiratory infections in periods of virus co-circulation)
IrelandNCPE
10/23/20Clinical evidence for the use of antivirals in the treatment of COVID-19
SpainAEMPS
10/23/20Sospechas de reacciones adversas notificadas con tratamientos utilizados en COVID-19 (Suspected adverse reactions reported with treatments used in COVID-19)
SpainAEMPS
10/23/20Sospechas de reacciones adversas notificadas con tratamientos utilizados en COVID-19 (Suspected adverse reactions reported with treatments used in COVID-19)
IrelandNCPE10/22/20Rapid Evidence Review – Clinical evidence for the use of antivirals in the treatment of COVID-19
ItalyAIFA
10/6/20Corticosteroidi nella terapia dei pazienti adulti con COVID-19 (Corticosteroids in the therapy of adult patients with COVID-19)
SpainAEMPS
10/2/20Información sobre investigación clínica sobre la COVID-19 (Information on clinical research on COVID-19)
FranceHAS
9/25/20Veille des études cliniques publiées pour certains médicaments du Covid-19 (Monitors published clinical studies for certain Covid-19 drugs)
SpainAQuAS9/22/20Símptomes de llarga durada o persistents en pacients amb infecció lleu-moderada per SARS-CoV-2 (COVID-19): revisió ràpida de la literatura i discussió del’evidència disponible (Long-term or persistent symptoms in patients with moderate SARS-CoV-2 infection (COVID-19): rapid literature review and discussion of available evidence )
PolandAOTMiT8/28/20Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation
IrelandNCPE
8/21/20Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation
AustriaAIHTA
8/18/20COVID-19/Horizon Scanning Living Document
FinlandFIMEA
8/7/20Fimea julkaisi arviointikoosteen remdesiviiristä COVID-19-taudin hoidossa (Fimea has published a summary of the evaluation of remdesivirir in the treatment of COVID-19)
PolandAOTMIT
8/6/20Przegląd doniesień naukowych dla kortykosteroidów stosowanych w COVID-19 (Assessment of the scientific reports for corticosteroids used in COVID-19 (version 1.0))
PolandAOTMIT
8/5/20Przegląd doniesień naukowych dla lopinawiru/rytonawiru stosowanych w COVID-19 (Overview of the scientific reports for lopinavir / ritonavir used in COVID-19 (version 1.0))
UKNICE6/5/20COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19
ItalyAIFA
7/17/20Darunavir/cobicistat nella terapia dei pazienti adulti con COVID-19 (Darunavir / cobicistat in the treatment of adult patients with COVID-19 )
ItalyAIFA
7/17/20Lopinavir/ritonavir nella terapia dei pazienti adulti con COVID-19 (Lopinavir / ritonavir in the treatment of adult patients with COVID-19 )
ItalyAIFA7/17/20Farmaci utilizzabili per il trattamento della malattia COVID-19 (Drugs usable for the treatment of the disease COVID-19)
WalesHTW7/??/20Cytokine adsorbers for the treatment of cytokine
storm in people with severe coronavirus infection
UKNICE National Institute for Health and Care Excellence6/29/20COVID-19 rapid evidence summary: vitamin D for COVID-19
UKNICE
National Institute for Health and Care Excellence

6/5/20COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19
UkraineMoH Ukraine
5/22/20Застосування ліків при COVID-19 (The use of drugs in COVID-19)
UKNICE
National Institute for Health and Care Excellence
3/24/20COVID-19 rapid evidence summary: acute use of nonsteroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19